Novo Nordisk’s new diabetes remedy Victoza has posted impressive uptake since its U.S. launch in February. But the company already has its eyes on broader use of the drug. Novo is eyeing the obesity-drug market, considering a Phase III trial of Victoza (liraglutide) in patients with severe obesity.

Novo CEO: Victoza worth study as obesity drug – FiercePharma.